Now What with Injectable LEN for PrEP?
How to Translate Ambition into Accelerated Delivery and Impact
The announcements on 9 July 2025 from Global Fund and Gilead about their next steps for injectable lenacapavir (LEN) for PrEP are welcome, as one more part of the process. But they raise as many questions as they answer. This brief summary is intended to help outline what is actually known – and not – and what needs to happen next.
Was this content helpful?
Tell us how we can improve the content.
Was this content helpful?
Thank you for your feedback!